Nadine Van Roy - Genetic Mutations

Author Information

Nadine Van Roy is affiliated with the Center for Medical Genetics at Ghent University Hospital in Ghent, Belgium. She is also associated with the Cancer Research Institute Ghent (CRIG) and the Department of Biomolecular Medicine at Ghent University. Her research primarily involves genetic and molecular studies related to cancer.

Research Contributions

Nadine Van Roy has made significant contributions to the field of cancer genetics. Her work spans various aspects of genetic research, including the identification of novel therapeutic targets for high-risk neuroblastoma, the feasibility of using liquid biopsies for cancer profiling, and the study of cytokine and therapy-induced PIM1 activation in T-cell acute lymphoblastic leukemia and lymphoma. One of her notable publications discusses a rare case of malignant pleural mesothelioma with an EML4-ALK fusion. Additionally, she has contributed to understanding the genetic mutations and amplifications in neuroblastoma, as well as the development of chronic myeloid leukemia in patients with previous myeloproliferative neoplasms.

Aliases

Nadine Van Roy is also known by the aliases N Van Roy and N. Van Roy in her publications.

Publication and Citation Metrics

Metric	Value
Total Citation Count	25,850
H-Index	46
Total Paper Count	153

Publications:

Malignant pleural mesothelioma with an EML4-ALK fusion: Expect the unexpected!

DOI: 10.1016/j.prp.2022.153772

Year: 2022

From DNA Copy Number Gains and Tumor Dependencies to Novel Therapeutic Targets for High-Risk Neuroblastoma

DOI: 10.3390/jpm11121286

Year: 2021

Extrauterine Mesonephric-like Neoplasms

DOI: 10.1097/PAS.0000000000001766

Year: 2021

The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples

DOI: 10.1016/j.ejca.2021.09.022

Year: 2021

Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)

DOI: 10.1200/JCO.21.00086

Year: 2021

Association of Unbalanced Translocation der(1;7) with Germline GATA2 Mutations.

DOI: 10.1182/blood.2021012781

Year: 2021

Abdominal ectopia cordis in an aborted calf without chromosomal aberrations

DOI: 10.21825/vdt.v90i4.20710

Year: 2021

Development of chronic myeloid leukemia in a patient previously diagnosed with a JAK2-positive myeloproliferative neoplasm

DOI: 10.1515/cclm-2020-1884

Year: 2021

Abstract B48: Minimally invasive classification of pediatric solid tumors using reduced representation bisulfite sequencing of cell-free DNA

DOI: 10.1158/1557-3265.liqbiop20-b48

Year: 2020

Targeting cytokine and therapy induced PIM1 activation in T-cell acute lymphoblastic leukemia and lymphoma.

DOI: 10.1182/blood.2019003880

Year: 2020

What Are Some Diseases Caused by Nucleotide Mutations?

What are Non-Coding Regions?

Can Neurodevelopmental Disorders Be Prevented?

What Genetic Conditions Are Commonly Addressed in Occupational Therapy?

What are the Ethical Concerns?

What are Common Applications of Gene Cloning?

What are the Key Techniques in Genetic Research?

What is Transversion?

Can Genetic Testing Help?

What are Inversions?

Partnered Content Networks

Relevant Topics